News

2023
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Release

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

Sep 7, 2022
View All

In the news

GeekWire

Nov 15, 2022

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies

Media

Genetic Engineering & Biotechnology News

Nov 15, 2022

From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines

Media

Endpoints News

Nov 15, 2022

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

Media

Biocentury

Sep 8, 2022

Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition

Media

BioWorld

Sep 7, 2022

Bonum to continue Good work after $250M cash acquisition deal with Roche

Media

Endpoints News

Sep 7, 2022

Good Therapeutics sells PD-1 IL-2 program to Roche for $250M and will march on with a similar name, but in Latin

Media
View All

Also seen in

Life Science Leader

A Recipe For Start-Up Success With A Platform Technology

Mar 1, 2023
Media

In Vivo Pharma Intelligence

The Busiest Dealmakers Of 2022

Dec 1, 2022
Media

Puget Sound Business Journal

Seattle biotech Bonum raises $93M Series A round

Nov 16, 2022
Media

The pharmaletter

Good Therapeutics spinout Bonum banks $93 million in Series A

Nov 16, 2022
Media

BioSpace

Good Therapeutics’ Offshoot Bonum Launches with $93 Million in Series A (Updated)

Nov 15, 2022
Media

FierceBiotech

Roche-backed Bonum bags $93M series A to develop new class of conditionally active therapies

Nov 15, 2022
Media

Wall Street Journal

Healthcare Investor Digitalis Ventures Nets $300 Million Fund

Oct 18, 2022
Media

Biopharmadive

Roche to pay $250M for Good Therapeutics and its targeted drug technology

Sep 7, 2022
Media
View All

Blog

Developing the Next Generation of Targeted, Conditionally Active Cytokine Therapeutics

Mar 30, 2023
Blog

Founder & CEO John Mulligan Shares Bonum Therapeutics’ “No Jerks” Approach to Hiring

Feb 14, 2023
Blog

6 Tips For Successful Drug Discovery Teamwork

Dec 16, 2022
Blog

The View from Business Development at Bonum Therapeutics

OCT 24, 2022
Blog

Welcome to Bonum Therapeutics

Sep 7, 2022
Blog
View All